| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/15/2007 | US7217796 Neutralizing human anti-IGFR antibody |
| 05/15/2007 | US7217736 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| 05/15/2007 | US7217734 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 05/15/2007 | US7217732 Cannabinoid receptor agonists |
| 05/15/2007 | US7217729 4,6-Dimethyl-3-{[3'-(N,N-dimethylaminomethyl)-4-hydroxy-4'-(3''-methoxyphenyl)-cyclohexylamino]-methyl}-1H-indole 2-carboxylic acid ethyl ester or other derivatives of substituted indoles; for treatment or prevention of neurodegenerative diseases, psychological disorders, AIDS, inflammation or allergies |
| 05/15/2007 | US7217710 Pyrazolo-pyrimidine compound; anticancer agents |
| 05/15/2007 | US7217539 Cell death inducers for mast cells |
| 05/15/2007 | US7217534 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 05/15/2007 | US7217419 Vaccine for preventing cervical cancer |
| 05/15/2007 | US7217413 Use of novel agents inducing cell death in synergy with interferons |
| 05/15/2007 | CA2437844C Method for increasing leptin levels using nicotinic acid compounds |
| 05/15/2007 | CA2399709C Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers |
| 05/15/2007 | CA2392973C Benzoimidazole derivatives useful as antiproliferative agents |
| 05/15/2007 | CA2366186C Retinoid antagonists and use thereof |
| 05/15/2007 | CA2255540C Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/15/2007 | CA2176948C Chaperonin 10 |
| 05/15/2007 | CA2149922C Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 05/15/2007 | CA2094705C Pharmaceutical composition for treating or preventing malign tumors |
| 05/10/2007 | WO2007053776A1 Pyrimidinyl-thiophene kinase modulators |
| 05/10/2007 | WO2007053718A1 Antibodies and immunotoxins that target human glycoprotein nmb |
| 05/10/2007 | WO2007053574A2 Combinations comprising sorafenib and interferon for the treatment of cancer |
| 05/10/2007 | WO2007053573A2 Treatment of cancer with sorafenib |
| 05/10/2007 | WO2007053346A1 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors |
| 05/10/2007 | WO2007052850A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 05/10/2007 | WO2007052849A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 05/10/2007 | WO2007052728A1 Method for improvement in transformation efficiency or homologous recombination efficiency in cell by using dna oligomer as carrier for gene delivery, and cell transformed using the method |
| 05/10/2007 | WO2007052629A1 Oligo double-stranded rna and pharmaceutical composition |
| 05/10/2007 | WO2007052267A2 Biodegradable composite for internal local radiotherapy |
| 05/10/2007 | WO2007052076A2 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 05/10/2007 | WO2007051862A1 Combination of organic compounds |
| 05/10/2007 | WO2007051622A1 Lead structures for cytostatic compounds based on spiro compounds |
| 05/10/2007 | WO2007051462A2 Use of tetraorganosilicon compounds |
| 05/10/2007 | WO2007051390A1 The use of eriocalyxin b in the manufacture of medicaments for treating leukemia |
| 05/10/2007 | WO2007051316A1 Inhibition of autophagy genes in cancer chemotherapy |
| 05/10/2007 | WO2007031574A3 Therapeutic use of outer shigella protein f (os pf) |
| 05/10/2007 | WO2007028347A3 Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug |
| 05/10/2007 | WO2007023281A3 Biologically active compounds |
| 05/10/2007 | WO2007022520A3 Antibody-mediated enhancement of immune response |
| 05/10/2007 | WO2007022102A3 Pentacyclic kinase inhibitors |
| 05/10/2007 | WO2007014169A3 Anti-cd26 antibodies and methods of use thereof |
| 05/10/2007 | WO2007013950A3 Combination therapy of her expressing tumors |
| 05/10/2007 | WO2007011693A3 Compositions of placentally-derived stem cells for the treatment of cancer |
| 05/10/2007 | WO2007010273A3 Use of thiazole derivatives and analogues in the treatment of cancer |
| 05/10/2007 | WO2007006171A8 A traditional chinese medicine composition, the preparation and quality controlling method thereof |
| 05/10/2007 | WO2007004526A3 Identification of compounds modulating the smyd3 transferase for the treatment of cancer |
| 05/10/2007 | WO2007003904A3 Prophylactic and immunomodulatory compositions and uses |
| 05/10/2007 | WO2006120573A3 Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors |
| 05/10/2007 | WO2006114387A3 Insp163 polypeptides for the treatment or prevention of cancer and arthritis |
| 05/10/2007 | WO2006105313A3 Compositions of and methods of using oversulfated glycosaminoglycans |
| 05/10/2007 | WO2006095016A3 Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane |
| 05/10/2007 | WO2006083961A3 Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders |
| 05/10/2007 | WO2006037090A3 Drug-phosphate conjugates as prodrugs |
| 05/10/2007 | US20070106082 4-(4-Hydroxy-phenyl)-2-methyl-1,2,3,3a,4,9b-hexahydro-cyclopenta[c]chromen-8-ol; estrogen receptor beta agonists; anticarcinogenic agent; prostate, testicular, ovarian, lung cancers, benign prostatic hyperplasia; cardiovascular diseases, neurodegenerative disorders, urinary incontinence, osteoporosis |
| 05/10/2007 | US20070105949 Intermediates for the preparation of lipoxin A4 analogs |
| 05/10/2007 | US20070105936 new crystals forms of Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate; VLA-4 (very late antigen-4) inhibitor; therapeutic drug for disorders caused by cell adhesion; water soluble, stability |
| 05/10/2007 | US20070105933 Amino alcohol compounds |
| 05/10/2007 | US20070105900 Pharmaceutical compounds |
| 05/10/2007 | US20070105893 e.g. 2-[(4-Ethoxyphenyl)methyl]-1-(3-methylbutyl)-N,N-bis(2,2,2-trifluoroethyl)-1H-benzimidazole-5-carboxamide; agonists at cannabinoid 2 receptor; analgesic agent, anticarcinogenic agent, neurodegenerative diseases; multiple sclerosis, Parkinson's disease, Huntington's chorea or Alzheimer's disease. |
| 05/10/2007 | US20070105886 Steroidal compounds for inhibiting steroid sulphatase |
| 05/10/2007 | US20070105860 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors |
| 05/10/2007 | US20070105859 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors |
| 05/10/2007 | US20070105840 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 05/10/2007 | US20070105812 Treating HIV-1 viral infections by administering a phospholipid choline derivative, e.g., 1-dodecanamido-2-decyloxypropyl-3-phosphocholine |
| 05/10/2007 | US20070105796 Method for inhibiting telomerase activity and inhibitor thereof |
| 05/10/2007 | US20070105773 Pharmaceutical composition comprising TrkAIg2 for use in the prevention and/or treatment of cancer |
| 05/10/2007 | US20070105191 Capable of inducing chondrocyte proliferation; Chinese Hamster Ovary, an Escheria coli or a yeast host cell with an expression vector |
| 05/10/2007 | US20070104759 Sustained release inserts; mixture of thermoplastic polyester, solvent and leuprolide acetate; prostate cancer |
| 05/10/2007 | US20070104733 Tissue targeted antigenic activation of the immune response to cancers |
| 05/10/2007 | US20070104731 Helicobacter proteins and vaccines |
| 05/10/2007 | US20070104720 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 05/10/2007 | US20070104719 Caspase Activated Prodrugs Therapy |
| 05/10/2007 | US20070104685 Synthetic gene encoding human carcinoembryonic antigen and uses thereof |
| 05/10/2007 | DE102006048362A1 Composition, useful to treat and/or protect disease condition e.g. circulatory disorder, comprises an active substance combination of isoflavone or isoflavone glycoside and a peptide derivative |
| 05/10/2007 | DE102005053213A1 Pharmaceutically active substance, useful to treat tumor diseases, comprises unpurified saliva obtained from animals of the genus Varanus, Timon, Lacerta and/or Podarcis |
| 05/10/2007 | DE102005053011A1 Use of tetraorganosilicon compound having cell proliferation inhibitory activity, e.g. as an immunstimulator to treat viral-, bacterial- and/or tumor diseases, anemia, arteriosclerosis, arthritis, asthma, autoimmune disease, and cirrhosis |
| 05/10/2007 | DE102005051631A1 Zubereitung und Anwendung eines Phytotherapeutikums Preparation and application of a phytotherapeutic |
| 05/10/2007 | CA2779041A1 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
| 05/10/2007 | CA2628477A1 Inhibition of autophagy genes in cancer chemotherapy |
| 05/10/2007 | CA2628474A1 Pyrimidinyl-thiophene kinase modulators |
| 05/10/2007 | CA2627890A1 Antibodies and immunotoxins that target human glycoprotein nmb |
| 05/10/2007 | CA2627875A1 Combinations comprising sorafenib and interferon for the treatment of cancer |
| 05/10/2007 | CA2627873A1 Treatment of cancer with sorafenib |
| 05/10/2007 | CA2627670A1 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors |
| 05/10/2007 | CA2627598A1 Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| 05/10/2007 | CA2626350A1 Compounds and compositions as protein kinase inhibitors |
| 05/10/2007 | CA2625096A1 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 05/10/2007 | CA2609985A1 Modulation of cell barrier dysfunction |
| 05/09/2007 | EP1783221A1 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 05/09/2007 | EP1783216A1 Telomerase-inhibitory ena oligonucleotide |
| 05/09/2007 | EP1783215A1 Angiostatin and method of use for inhibition of angiogenesis |
| 05/09/2007 | EP1783141A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/09/2007 | EP1783139A2 Human telomerase catalytic subunit |
| 05/09/2007 | EP1783126A2 N-oxides of N-phenyl-2-pyrimidine-amine derivatives |
| 05/09/2007 | EP1782838A1 Inhibition of infiltration, and cell killing agent |
| 05/09/2007 | EP1782833A2 pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
| 05/09/2007 | EP1782828A1 Progression inhibitor for disease attributed to abnormal accumulation of liver fat |
| 05/09/2007 | EP1782827A1 Peptide vaccine for cancer therapy |
| 05/09/2007 | EP1782826A1 PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 05/09/2007 | EP1782822A1 Remedy for melaonoma |
| 05/09/2007 | EP1782817A1 Pharmaceutical preparation made from the oral secretion of Varanus, Timon, Lacerta and/or Podarcis for tumour treatment |